ABT Aqua Bio Technology

Aqua Bio Technology: Positive decision in legal dispute in Sweden

Aqua Bio Technology: Positive decision in legal dispute in Sweden

After a long dispute between Aqua Bio Technology and a Swedish customer, the District Court of Helsingborg, Sweden ruled that ABT violated a delivery commitment in 2015. However, the customer’s claim of a NOK 12.2 million compensation has been rejected by the court.

The Swedish company Zona Nordic filed a legal complaint against Aqua Bio Technology in 2018, arguing that ABT had failed to deliver an agreed volume of the ingredient Zonase for use in Zona Nordic’s skincare products (reference is made to ABT’ announcement 18.06.2018). Zona Nordic demanded a NOK 12.2 million compensation, claiming that this was the market value of the ingredient volume not delivered. ABT rejected the claim, arguing that obligations towards Zona Nordic had been met and that the claim was without merit.

The Helsingborg District Court today ruled that Aqua Bio Technology did violate its commitment in 2015, however the court found the NOK 12.2 million compensation demand without basis. The court set the compensation to approximately NOK 350,00 representing the agreed book value of the obligation to deliver the ingredient.

The court found that Zona Nordic’s claim for compensation was unreasonably high as it was clear that the company failed to prove losses at the claimed level. The court also found that Zona Nordic would have been unable to make use of the disputed ingredient volume, had it been delivered.

Zona Nordic still may sell and distribute Zonase in two brands outside of the Nordic Countries, and the court therefore found that Zona Nordic AB shall compensate ABT for appr. 50 per cent of ABT’s legal costs, representing a payment to ABT of approximately NOK 600,000.

For further information, please contact Mr Edvard Cock, Chairman of Aqua Bio Technology ASA, telephone  004.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. 

EN
10/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aqua Bio Technology

 PRESS RELEASE

Aqua Bio Technology ASA: Safety studies of 6 products from the product...

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approvedReference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 1...

 PRESS RELEASE

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produkts...

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent Det vises til børsmelding av vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være e...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with...

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform Restorsea's commercialization of Aqua Bio Technologies ASA's hatching fluid ingredient (Aquabeautine XL) continues. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. In connection with Hydrafacial`s merger with Vesper Healthcare and the contemplated listing on (NASDAQ), Restorsea is presented as . In Q3 20...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restors...

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter. Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs. I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på (NASDAQ), presenteres Restorsea som . Hydrafacial opplyser at selskapet per Q3 2020 har utpl...

 PRESS RELEASE

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - dis...

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - distribution agreement for New Zealand and Australia close Reference is made to where it is informed that Aqua Bio Technology ASA (ABT) is acquiring all rights to Moana Skincare . This acquisition has now been completed and in the near future ABT expects to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled na...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch